암 게놈 프로파일링 시장 - 전략적 인사이트와 예측(2026-2035년)

The Cancer Genomic Profiling Market is set to reach USD 23.14 billion in 2035, growing at a CAGR of 11.7 % from USD 8.58 billion in 2026.

The cancer genomic profiling market is undergoing significant transformation driven by the paradigm shift toward precision oncology and the growing recognition that comprehensive molecular characterization is essential for personalized cancer treatment. The market's evolution is characterized by the increasing adoption of next-generation sequencing and multi-omics approaches to identify actionable mutations, guide therapy selection, and monitor disease progression across multiple cancer types. The convergence of advanced sequencing technologies, artificial intelligence, and liquid biopsy platforms is enabling faster, more comprehensive, and increasingly accessible genomic analysis. Healthcare systems worldwide are expanding genomic testing capabilities as targeted therapies and immunotherapies require biomarker-driven patient selection. The market is witnessing significant investment in comprehensive genomic profiling, companion diagnostics, and bioinformatics solutions, positioning cancer genomic profiling as a cornerstone of modern oncology practice.

Market Drivers

• The growing adoption of precision oncology represents the primary driver for the cancer genomic profiling market. Precision medicine requires comprehensive genomic profiling to identify actionable mutations and personalize cancer treatment strategies. Healthcare providers are expanding genomic testing programs to support targeted therapy selection and improve patient outcomes. Diagnostic manufacturers are developing comprehensive genomic profiling solutions to capture growing demand. This requirement strengthens demand for genomic testing across all cancer types, resulting in sustained growth in cancer genomic profiling utilization. Rapid advancements in next-generation sequencing technologies are further accelerating market growth through improved diagnostic accuracy, throughput, affordability, and accessibility across clinical laboratories worldwide. Continuous innovation in sequencing chemistry, automation, and bioinformatics is expanding the clinical utility of genomic profiling. Technology developers are reducing sequencing costs while improving analytical performance. These advancements support broader clinical adoption and increased testing volumes. Expanding approvals of targeted therapies and companion diagnostics are accelerating routine genomic testing in oncology clinical practice and research. Regulatory approvals for biomarker-driven therapies create sustained demand for companion diagnostic testing. Pharmaceutical companies are expanding targeted therapy pipelines that require genomic characterization for patient selection. Diagnostic manufacturers are developing companion diagnostic solutions to support therapeutic approvals and commercialization. Rising global cancer incidence and increasing biomarker-driven treatment approaches strengthen demand for comprehensive molecular profiling solutions. Growing cancer burden creates sustained demand for diagnostic testing across screening, diagnosis, treatment selection, and monitoring applications. Healthcare systems are expanding genomic testing capacity to support personalized treatment strategies.

Market Restraints

• High costs of genomic sequencing platforms and bioinformatics infrastructure limit adoption among smaller hospitals and diagnostic laboratories. The significant financial investment required for advanced technologies creates barriers for smaller facilities. Limited reimbursement coverage for comprehensive genomic profiling remains a barrier in several emerging healthcare markets. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Complex genomic data interpretation requires specialized expertise and advanced bioinformatics capabilities, restricting widespread clinical implementation. The shortage of trained personnel and bioinformatics infrastructure limits the scalability of genomic profiling. Variability in regulatory requirements across countries delays commercialization and global adoption of advanced genomic profiling technologies.

Technology and Profiling Type Insights

• The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated bioinformatics platforms. NGS dominates the technology landscape because of its ability to simultaneously analyze multiple genomic alterations with high sensitivity and throughput. PCR remains widely utilized for targeted mutation detection and companion diagnostics. FISH continues serving an important role in chromosomal abnormality analysis. Microarray technology supports gene expression profiling. Sanger sequencing remains valuable for confirmatory testing and validation. The segment analysis reveals that comprehensive genomic profiling is the fastest-growing profiling type due to increasing demand for broad molecular characterization to guide treatment decisions. Targeted gene panel profiling remains important for focused analysis of clinically actionable genes. WES and WGS are expanding for research and specific clinical applications where comprehensive genomic information is required. Tissue samples remain the gold standard for comprehensive genomic profiling due to their ability to provide high-quality DNA and complete tumor characterization. Blood samples are witnessing the fastest growth as liquid biopsy technologies enable minimally invasive genomic testing, treatment monitoring, and recurrence detection. Therapy selection represents the primary clinical application, with companion diagnostics and prognostic assessment experiencing rapid growth. Hospitals and diagnostic laboratories represent the leading end-user segments, with cancer centers and academic research institutes expanding genomic testing capabilities. The integration of AI is becoming increasingly important as AI-powered bioinformatics enhances genomic data interpretation, clinical decision support, and precision oncology workflow efficiency.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized genomic testing, bioinformatics, and liquid biopsy providers. Roche develops comprehensive molecular diagnostics, companion diagnostics, sequencing technologies, and precision oncology solutions supporting genomic profiling. Illumina is a global leader in NGS platforms enabling comprehensive cancer genomic profiling and precision medicine. Thermo Fisher Scientific provides sequencing systems, PCR technologies, genomic analysis solutions, and oncology research platforms. QIAGEN develops molecular diagnostics, sample preparation technologies, PCR assays, and bioinformatics solutions supporting genomic testing. Agilent delivers genomics instrumentation, molecular assays, automation technologies, and bioinformatics solutions for oncology diagnostics. Danaher provides advanced genomics platforms, molecular diagnostic technologies, sequencing solutions, and laboratory automation systems. Guardant Health specializes in liquid biopsy, comprehensive genomic profiling, and precision oncology testing for advanced cancer management. Exact Sciences develops molecular cancer diagnostics, genomic profiling technologies, and precision oncology testing solutions. Foundation Medicine specializes in comprehensive genomic profiling, companion diagnostics, and precision oncology testing. Companies are pursuing product portfolio expansion through innovation in NGS platforms, liquid biopsy assays, and AI-enabled bioinformatics. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Illumina expanding oncology sequencing capabilities with enhanced comprehensive genomic profiling workflows. Roche strengthened its precision oncology portfolio through expanded companion diagnostic collaborations. Thermo Fisher Scientific introduced advanced NGS workflow solutions for clinical oncology laboratories. Guardant Health expanded liquid biopsy applications supporting comprehensive genomic profiling.

Short Conclusion

• The cancer genomic profiling market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and expanding healthcare investment. The transition from single-gene testing toward comprehensive genomic profiling represents a fundamental shift in oncology practice. While challenges related to high costs, reimbursement limitations, and data interpretation complexity persist, strategic investments in technology, partnerships, and bioinformatics are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with cancer genomic profiling evolving into a cornerstone of modern oncology, supporting personalized treatment selection, therapy monitoring, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Cancer Genomic Profiling Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Evolution of Cancer Genomic Profiling
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Cancer Patient Population Analysis
• 3.8 Genomic Testing Volume Analysis
• 3.9 Precision Oncology Adoption Analysis
• 3.10 Clinical Workflow Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Comprehensive Genomic Profiling Advancements
• 6.4 Artificial Intelligence in Genomic Data Interpretation
• 6.5 Multi-Omics Integration
• 6.6 Liquid Biopsy-Based Genomic Profiling
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Cancer Genomic Profiling Market Landscape Analysis

• 8.1 Analysis by Profiling Type
  • 8.1.1 Comprehensive Genomic Profiling
  • 8.1.2 Targeted Gene Panel Profiling
  • 8.1.3 Whole Exome Sequencing (WES)
  • 8.1.4 Whole Genome Sequencing (WGS)
• 8.2 Analysis by Technology
  • 8.2.1 Next-Generation Sequencing (NGS)
  • 8.2.2 Polymerase Chain Reaction (PCR)
  • 8.2.3 Fluorescence In Situ Hybridization (FISH)
  • 8.2.4 Microarray
  • 8.2.5 Sanger Sequencing
• 8.3 Analysis by Biomarker Type
  • 8.3.1 Single Nucleotide Variants (SNVs)
  • 8.3.2 Copy Number Variations (CNVs)
  • 8.3.3 Gene Fusions
  • 8.3.4 Microsatellite Instability (MSI)
  • 8.3.5 Tumor Mutational Burden (TMB)
• 8.4 Analysis by Clinical Application
  • 8.4.1 Therapy Selection
  • 8.4.2 Companion Diagnostics
  • 8.4.3 Prognostic Assessment
  • 8.4.4 Disease Monitoring
  • 8.4.5 Clinical Research

9. Global Cancer Genomic Profiling Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Bioinformatics
• 9.2 By Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Polymerase Chain Reaction (PCR)
  • 9.2.3 Fluorescence In Situ Hybridization (FISH)
  • 9.2.4 Microarray
  • 9.2.5 Sanger Sequencing
  • 9.2.6 Other Technologies
• 9.3 By Sample Type
  • 9.3.1 Tissue Samples
  • 9.3.2 Blood Samples
  • 9.3.3 Bone Marrow Samples
  • 9.3.4 Other Sample Types
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Diagnostic Laboratories
  • 9.4.3 Cancer Centers
  • 9.4.4 Academic & Research Institutes

10. Global Cancer Genomic Profiling Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Cancer Genomic Profiling Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Illumina, Inc.
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Thermo Fisher Scientific Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 QIAGEN N.V.
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 Agilent Technologies, Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 Danaher Corporation
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 Guardant Health, Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 Exact Sciences Corporation
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Foundation Medicine, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 Tempus AI, Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 NeoGenomics Laboratories, Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Personalis, Inc.
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 Caris Life Sciences
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 Bio-Rad Laboratories, Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 Abbott Laboratories
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Cancer Genomic Profiling Market Commercial Forecast Analysis

• 14.1 Comprehensive Genomic Profiling (CGP) Tests
• 14.2 Targeted Gene Panel Tests
• 14.3 Whole Exome Sequencing (WES)
• 14.4 Whole Genome Sequencing (WGS)
• 14.5 Liquid Biopsy-Based Genomic Profiling
• 14.6 Companion Diagnostic Genomic Tests
• 14.7 Bioinformatics and Genomic Interpretation Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends